ERBB2 status and benefit from adjuvant tamoxifen in ER alpha-positive postmenopausal breast carcinoma

I Bieche, P Onody, F Lerebours, S Tozlu, K Hacene, C Andrieu, M Vidaud, M Tubiana-Hulin, F Spyratos, R Lidereau

Research output: Contribution to journalArticle (Academic Journal)peer-review

8 Citations (Scopus)

Abstract

We examined the relation between ERBB2 gene expression (as determined by a real-time quantitative RT-PCR assay) and the response to adjuvant tamoxifen therapy in a well-defined cohort of 125 ER alpha -positive postmenopausal patients with breast cancer. Although ERBB2 overexpression was associated with shorter relapse-free survival in univariate analysis (P = 0.00029), ERBB2 did not persist as an independent prognostic factor in multivariate analysis. Nevertheless, when we analyzed the ERBB2 mRNA level as a continuous variable, the higher the ERBB2RNA level, the poorer the outcome (P = 0.00036). The results point to the need for a quantitative ERBB2 expression assay for use in future studies of ERBB2-based clinical management of breast cancer. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
Translated title of the contributionERBB2 status and benefit from adjuvant tamoxifen in ER alpha-positive postmenopausal breast carcinoma
Original languageEnglish
Pages (from-to)173 - 178
JournalCancer Letters
Volume174 (2)
Publication statusPublished - Dec 2001

Bibliographical note

Publisher: Elsevier Sci Ireland Ltd
Other identifier: IDS Number: 494AH

Fingerprint Dive into the research topics of 'ERBB2 status and benefit from adjuvant tamoxifen in ER alpha-positive postmenopausal breast carcinoma'. Together they form a unique fingerprint.

Cite this